Pfizer Inc. (NYSE:PFE) Shares Acquired by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 110.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 227,323 shares of the biopharmaceutical company's stock after buying an additional 119,111 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Pfizer were worth $6,031,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. grew its position in shares of Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after purchasing an additional 5,153,257 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Up 1.8 %

Shares of PFE stock traded up $0.42 during trading hours on Wednesday, reaching $24.21. The company had a trading volume of 26,018,296 shares, compared to its average volume of 40,764,661. The company has a market capitalization of $137.31 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock's fifty day simple moving average is $24.48 and its 200 day simple moving average is $25.86.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.10%. Pfizer's dividend payout ratio is presently 121.99%.

Analysts Set New Price Targets

A number of analysts have issued reports on PFE shares. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $29.64.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.